Funder
National Key Research and Development Program of China
Key Technologies R and D Program of Sichuan
key projects of central universities
Guizhou Yi Bai Pharmaceutical Co., Ltd
Subject
Immunology,Immunology and Allergy
Reference67 articles.
1. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum.,2006
2. Rheumatoid arthritis;Klareskog;Lancet,2009
3. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013;Vos;Lancet,2015
4. Promising bone-related therapeutic targets for rheumatoid arthritis, Nature reviews;Choi;Rheumatology,2009
5. Development of rheumatoid arthritis drugs in the world;Liu;Sci. Technol. Rev.,2016
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献